Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Description
Adolescents with Opioid Use Disorder (A-OUD) and psychiatric co-morbidities can have good outcomes with appropriate, early treatment, but most do not receive it. This course will teach a rapid screening tool for identification of adolescent substance use disorder and discuss how to handle the first discussion with a patient and family about a new OUD diagnosis. Evidence for efficacy of medications used for treatment of A-OUD will be explored, medication interactions with psychiatric meds reviewed, and gaps in the literature identified. The roles of parents, contingency management, diet, and other lifestyle factors will be reviewed as part of a patient-centered treatment plan.
Please note you must complete all 4 modules in order to claim credit for this course.
Titles of Modules:
- Identification and initial treatment steps for adolescent opioid use disorder
- Naltrexone, weight, and nutrition in Adolescent OUD
- Opioid agonist treatment in adolescent OUD: buprenorphine and beyond
- Enlisting parents and contingency management in adolescent OUD
Pricing
FREE - $0
Learning Objectives
- Learn to use a brief screening tool, the Screen to Brief Intervention (S2BI), for identification and risk stratification of substance use disorders in adolescents ages 12-17 years, which can be used in any treatment setting.
- Develop a strategy when a new diagnosis of OUD is made with concrete steps and strategies for guiding the discussion.
- Review the evidence base for use of buprenorphine-naloxone in Adolescents with Opioid Use Disorder (A-OUD), drug interactions with common psychiatric medications, and identify gaps in the literature.
- Review evidence base for use of naltrexone (oral and injectable) in A-OUD, drug interactions with common psychiatric medications, and identify gaps in the literature.
- Learn principles of Contingency Management (CM) which can be taught to parents to improve outcomes, with consideration for how psychiatric comorbidities may dictate fine-tuning of the CM plans.
Target Audience
Psychiatrists
Estimated Time to Complete
Estimated Duration: 5.0 hours
Program Begin Date: August 28, 2023
Program End Date: September 24, 2023
Credit Claim End Date: November 23, 2023
How to Earn Credit
After evaluating the program, participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the event date and hours earned.
Continuing Education Credit
In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The APA designates this enduring activity for a maximum of 5 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Planner Disclosures
The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Instructor:
- Diana Deister, MD. Reports no financial relationships with commercial interests.
Planners:
- Diana Deister, MD. Reports no financial relationships with commercial interests.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.